Biocon's stock hit a lifetime high after confirming the efficacy and safety of a biosimilar cancer drug it co-developed with Mylan compared to a branded drug. Biocon and Mylan will present clinical study data on the drug at the ASCO Annual Meeting in June. Biocon's stock has surged 30% since late April following its quarterly results announcement.

1. 06.06.2016 Today Biocon hits lifetime high of Rs 734.80 on the National Stock Exchange (NSE) after the
company and global pharma major Mylan Inc confirmed the efficacy and safety of MYL-1401O, a
proposed biosimilar trastuzumab co-developed by the firms, in comparison to a branded cancer drug.
In a statement Biocon said that the companies will present data from a clinical study during the ASCO
Annual Meeting being held in Chicago from June 3-7 2016.
Biocon has surged 30 percent from Rs 564 to Rs 734 since April 26, after it announced the quarter 4
results for FY 2015-16.
At 11.53 am, the stock of the company was trading 3.80 percent up at Rs 729.90 on the NSE.
For more informative, crisp and latest trending news on Stock Markets and Investment, keep
visiting www.moneypalm.in